Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.

@article{Puoti2006ImpactOL,
  title={Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.},
  author={Massimo Puoti and A. Cozzi-lepri and Giuseppe Paraninfo and Claudio Arici and Nina Friis Moller and Jens D. Lundgren and Bruno Ledergerber and Martin Rickenbach and Ignacio Su{\'a}rez-Lozano and Myriam Garrido and François Dabis and Maria Winnock and L Milazzo and Anne C. Gervais and François Raffi and John Gill and J{\"u}rgen K. Rockstroh and Nazifa Ourishi and Cristina Mussini and Antonella Castagna and Andrea De Luca and Antonella d'Arminio Monforte},
  journal={Antiviral therapy},
  year={2006},
  volume={11 5},
  pages={567-74}
}
BACKGROUND The impact of lamivudine (3TC) as part of combination antiretroviral therapy (cART) on the risk of liver-related death (LRD) in HIV/hepatitis B virus (HBV)-coinfected patients has not been extensively studied. METHODS We performed an analysis involving HIV/HBV-coinfected patients in 13 cohorts who initiated cART. The end-point was LRD--that is, death with concomitant decompensated liver disease (DLD) or hepatocellular carcinoma--as the main cause. Incidence rates of LRD after… CONTINUE READING